Briacell Net Income from 2010 to 2026
| BCT Stock | 15.22 4.58 43.05% |
Net Loss | First Reported 2006-10-31 | Previous Quarter -18.3 M | Current Value -8.2 M | Quarterly Volatility 4.8 M |
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 45.6 M, Total Operating Expenses of 45.4 M or Depreciation And Amortization of 178.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.19. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
Briacell | Net Income |
Latest Briacell Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Briacell Therapeutics Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Briacell Therapeutics financial statement analysis. It represents the amount of money remaining after all of Briacell Therapeutics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Briacell Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Briacell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (26.56 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Briacell Net Income Regression Statistics
| Arithmetic Mean | (8,892,757) | |
| Geometric Mean | 1,057,509 | |
| Coefficient Of Variation | (145.90) | |
| Mean Deviation | 10,348,634 | |
| Median | (2,584,122) | |
| Standard Deviation | 12,974,600 | |
| Sample Variance | 168.3T | |
| Range | 37.9M | |
| R-Value | (0.71) | |
| Mean Square Error | 89.1T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (1,824,101) | |
| Total Sum of Squares | 2693.4T |
Briacell Net Income History
About Briacell Therapeutics Financial Statements
Briacell Therapeutics investors utilize fundamental indicators, such as Net Income, to predict how Briacell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -23.9 M | -22.7 M | |
| Net Loss | -23.7 M | -22.5 M | |
| Net Loss | -4.4 M | -4.7 M | |
| Net Loss | (77.63) | (81.51) | |
| Net Income Per E B T | 1.14 | 1.08 |
Pair Trading with Briacell Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Briacell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Briacell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Briacell Stock
| 0.67 | FFH-PI | Fairfax Financial | PairCorr |
| 0.65 | AX-UN | Artis Real Estate | PairCorr |
| 0.57 | FFH | Fairfax Financial | PairCorr |
| 0.55 | KTO | K2 Gold | PairCorr |
| 0.54 | ENB-PFU | Enbridge Pref L | PairCorr |
The ability to find closely correlated positions to Briacell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Briacell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Briacell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Briacell Therapeutics Corp to buy it.
The correlation of Briacell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Briacell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Briacell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Briacell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Briacell Therapeutics Correlation against competitors. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.